Monday, July 12, 2010

Mesothelioma Survival Rates

Mesothelioma Survival Rates

Many studies have been conducted in regards to survival rates among mesothelioma patients. When discussing survival rates for this or any type of cancer, references to the "five-year relative survival rate" are often stated. This number refers to the percentage of patients who live at least five years after their cancer is diagnosed.

According to statistics published by the American Cancer Society, the five-year relative survival rate for patients with mesothelioma is approximately 10 percent. That number has improved in the last five years, up from 9 percent reported at the end of 2002. In addition, recent studies show that the one-year survival rate is now about 40 percent, a number that has also increased in the past five years. Throughout the 1990s, it was rare for a patient to survive more than a year after diagnosis.

Though numerous factors affect a patient’s prognosis such as age, overall health, and the type of mesothelioma the patient is battling, the average length of survival reported throughout the last five years has been 10 to 11 months after diagnosis.

Exciting stories about mesothelioma survivors continue to surface, providing hope to mesothelioma patients and their loved ones. Click here to read more about mesothelioma survivors.

Sources:

  1. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_ statistics_for_malignant_mesothelioma_29.asp?sitearea=
  2. http://www.cancer.org/docroot/CRI/content/CRI_2_4_5X_What_should_you_ask_your_physician _about_malignant_mesothelioma_29.asp?sitearea=
  3. http://www.cancer.gov/cancertopics/pdq/treatment/malignantmesothelioma/patient#Keypoint5

Mesothelioma Prognosis

Mesothelioma Prognosis

Approximately 2,000 to 3,000 new cases of mesothelioma are diagnosed in the United States each year. Once a patient is diagnosed, a doctor will likely discuss their prognosis, or probable course and outcome of the cancer's influence on the body.

The best way to avoid a poor prognosis is through early detection.

In an effort to help patients understand their prognosis, Asbestos.com offers a complimentary packet that contains treatment information tailored to your specific diagnosis. The packet also covers the nation's top mesothelioma doctors and cancer centers, as well as financial assistance options to help cover medical costs. To receive your packet in the mail, please enter your information below.

What Factors Affect Prognosis?

Mesothelioma is not generally diagnosed until the latest stages of development because of the amount of time it takes for patients to display symptoms associated with the disease. In addition to this, the symptoms of mesothelioma are very general and often resemble less serious conditions, which can make the cancer difficult to diagnose. As a result, the prognosis for the majority of patients is poor, but many doctors can recommend treatment options such as surgery, chemotherapy and radiation to help combat the disease.

Doctors typically address the cancer in terms of stages, ranging from stage one to stage four. Unfortunately, once mesothelioma cancer has reached stage three or four, treatment options not only become more limited but less effective as well. When a patient is diagnosed with stage four mesothelioma, their health condition often rules out the possibility of surgery. Treating mesothelioma becomes more difficult the later a diagnosis occurs.

Asbestos.com offers a complimentary packet containing information about treatment options and top doctors that may be able to help improve a patient’s prognosis. Click here to receive your packet overnight.

In addition to the stage of the cancer and the age of the patient, other factors that affect prognosis include:

  • The type of mesothelioma – pleural, peritoneal, pericardial or testicular
  • The size of the tumor
  • The location of the tumor and whether it can be surgically removed
  • The extent of other symptoms, including fluid in the lungs or abdomen
  • Whether or not the patient is a smoker

Malignant mesothelioma is typically diagnosed in individuals over 55 years old, though there are certainly exceptions. Some patients already have multiple medical problems caused by advancing age, making treatment even more difficult and increasing the mortality rate among mesothelioma patients.

Wednesday, June 30, 2010

General signs and symptoms of Mesotheloma

he signs and symptoms of mesothelioma cancer common to all types include:
  • Unexplained weight loss
  • Changes in appetite
  • Trouble swallowing
  • Pain in the neck of face
  • Blood clotting abnormalities
  • Fever
  • Anemia
  • Fatigue
  • Jaundice
  • Low blood sugar

Many of these symptoms and signs of mesothelioma cancer develop in the later stages, after the cancer has spread (metasticized) to other areas of the body. Mesothelioma cancer does not typically spread to the bone, brain, or adrenal glands.

Symptoms of Pleural Mesothelioma

Pleural mesothelioma, which affects the lining of the lungs and chest cavity, can produce the following signs and symptoms:

  • Shortness of breath
  • Fluid in the cavity between the lungs and chest wall (pleural efflusion)
  • Chest pain
  • Wheezing or hoarseness
  • Persistent cough, sometimes producing bloody sputum

Symptoms of Pericardial Mesothelioma

Pericardial mesothelioma, which affects the lining of the heart, can cause the following symptoms:

  • Chest pain, ranging from mild to severe
  • Shortness of breath
  • Heart palpitations
  • Persistent cough

Symptoms of Peritoneal Mesothelioma

Peritoneal malignant mesothelioma, which affects the lining of the abdomen, can cause the following:

  • Abdominal swelling
  • Malnutrition
  • Abdominal pain
  • Bowel Obstruction
  • Ascites, or buildup of fluid in the abdomen

It is important to understand that many of these mesothelioma cancer symptoms can be caused by mesothelioma or by other, less serious conditions. The only way to know be sure of your mesothelioma symptoms experienced is to have a complete medical examination and specific tests.

http://www.mesotheliomatreatmentcenters.org/mesotheloma/

Tuesday, June 22, 2010

Malignant Mesothelioma

Malignant Mesothelioma

Malignant mesothelioma is a form of asbestos cancer that affects the thin tissue layer surrounding the body's internal organs, called the mesothelium. The cancer is almost exclusively caused by asbestos exposure.

In an effort to help patients understand mesothelioma, Asbestos.com offers a complimentary packet that contains treatment information tailored to your specific diagnosis. The packet also covers the nation's top mesothelioma doctors and cancer centers, as well as financial assistance options to help cover medical costs.

Malignant Mesothelioma Types

How Many and What Type of Malignant Mesothelioma Deaths Occurred in 1999.

Medical professionals divide malignant mesothelioma into various types depending on which area of the mesothelium is affected:

  • Pleural mesothelioma is the most common form of the cancer, affecting the lining of the lungs, called the pleura.
  • Peritoneal mesothelioma is the second most common form of the cancer and develops in the lining of the abdomen, called the peritoneum.
  • Pericardial mesothelioma develops in the membrane that surrounds the heart, called the pericardium.
  • Testicular mesothelioma is the rarest form of the cancer and develops in the membranous lining surrounding the testicles, called the tunica vaginalis.

Malignant Mesothelioma Symptoms

Patients with malignant mesothelioma generally do not display any symptoms until 20 to 50 years after exposure to asbestos occurs. This is due to the long latency period (the amount of time it takes for a patient to demonstrate symptoms after initial exposure to a disease-causing agent) associated with mesothelioma. The symptoms of mesothelioma are very general and often resemble less serious conditions, which can make diagnosis difficult.

Symptoms vary depending on the type of mesothelioma a patient has, but the most common symptoms expressed by pleural mesothelioma patients include shortness of breath, chest pain and persistent cough. Peritoneal mesothelioma patients may display symptoms such as abdominal swelling, changes in bowel movement and development of lumps under the skin on the abdomen. Patients with pericardial mesothelioma may experience heart palpitations, chest pain, difficulty breathing and fever or night sweats. Testicular mesothelioma patients may notice testicular lumps.

Asbestos.com offers a complimentary informational packet personalized to a patient’s specific mesothelioma diagnosis. With information about the cancer, treatment options and top doctors, many patients and their loved ones find the packet to be a valuable resource.

http://www.asbestos.com/mesothelioma/malignant/


Monday, June 21, 2010

Mesothelioma Screening

Screening

There is no universally agreed protocol for screening people who have been exposed to asbestos. Screening tests might diagnose mesothelioma earlier than conventional methods thus improving the survival prospects for patients. The serum osteopontin level might be useful in screening asbestos-exposed people for mesothelioma. The level of soluble mesothelin-related protein is elevated in the serum of about 75% of patients at diagnosis and it has been suggested that it may be useful for screening.[24] Doctors have begun testing the Mesomark assay which measures levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells.[25]

Pathophysiology

The mesothelium consists of a single layer of flattened to cuboidal cells forming the epithelial lining of the serous cavities of the body including the peritoneal, pericardial and pleural cavities. Deposition of asbestos fibers in the parenchyma of the lung may result in the penetration of the visceral pleura from where the fiber can then be carried to the pleural surface, thus leading to the development of malignant mesothelial plaques. The processes leading to the development of peritoneal mesothelioma remain unresolved, although it has been proposed that asbestos fibers from the lung are transported to the abdomen and associated organs via the lymphatic system. Additionally, asbestos fibers may be deposited in the gut after ingestion of sputum contaminated with asbestos fibers.

Pleural contamination with asbestos or other mineral fibers has been shown to cause cancer. Long thin asbestos fibers (blue asbestos, amphibole fibers) are more potent carcinogens than "feathery fibers" (chrysotile or white asbestos fibers).[6] However, there is now evidence that smaller particles may be more dangerous than the larger fibers. They remain suspended in the air where they can be inhaled, and may penetrate more easily and deeper into the lungs. "We probably will find out a lot more about the health aspects of asbestos from [the World Trade Center attack], unfortunately," said Dr. Alan Fein, chief of pulmonary and critical-care medicine at North Shore-Long Island Jewish Health System. Dr. Fein has treated several patients for "World Trade Center syndrome" or respiratory ailments from brief exposures of only a day or two near the collapsed buildings.[26]

Mesothelioma development in rats has been demonstrated following intra-pleural inoculation of phosphorylated chrysotile fibers. It has been suggested that in humans, transport of fibers to the pleura is critical to the pathogenesis of mesothelioma. This is supported by the observed recruitment of significant numbers of macrophages and other cells of the immune system to localized lesions of accumulated asbestos fibers in the pleural and peritoneal cavities of rats. These lesions continued to attract and accumulate macrophages as the disease progressed, and cellular changes within the lesion culminated in a morphologically malignant tumor.

Experimental evidence suggests that asbestos acts as a complete carcinogen with the development of mesothelioma occurring in sequential stages of initiation and promotion. The molecular mechanisms underlying the malignant transformation of normal mesothelial cells by asbestos fibers remain unclear despite the demonstration of its oncogenic capabilities. However, complete in vitro transformation of normal human mesothelial cells to malignant phenotype following exposure to asbestos fibers has not yet been achieved. In general, asbestos fibers are thought to act through direct physical interactions with the cells of the mesothelium in conjunction with indirect effects following interaction with inflammatory cells such as macrophages.

Analysis of the interactions between asbestos fibers and DNA has shown that phagocytosed fibers are able to make contact with chromosomes, often adhering to the chromatin fibers or becoming entangled within the chromosome. This contact between the asbestos fiber and the chromosomes or structural proteins of the spindle apparatus can induce complex abnormalities. The most common abnormality is monosomy of chromosome 22. Other frequent abnormalities include structural rearrangement of 1p, 3p, 9p and 6q chromosome arms.

Common gene abnormalities in mesothelioma cell lines include deletion of the tumor suppressor genes:

Asbestos has also been shown to mediate the entry of foreign DNA into target cells. Incorporation of this foreign DNA may lead to mutations and oncogenesis by several possible mechanisms:

  • Inactivation of tumor suppressor genes
  • Activation of oncogenes
  • Activation of proto-oncogenes due to incorporation of foreign DNA containing a promoter region
  • Activation of DNA repair enzymes, which may be prone to error
  • Activation of telomerase
  • Prevention of apoptosis

Asbestos fibers have been shown to alter the function and secretory properties of macrophages, ultimately creating conditions which favour the development of mesothelioma. Following asbestos phagocytosis, macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences.

Asbestos also may possess immunosuppressive properties. For example, chrysotile fibres have been shown to depress the in vitro proliferation of phytohemagglutinin-stimulated peripheral blood lymphocytes, suppress natural killer cell lysis and significantly reduce lymphokine-activated killer cell viability and recovery. Furthermore, genetic alterations in asbestos-activated macrophages may result in the release of potent mesothelial cell mitogens such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β) which in turn, may induce the chronic stimulation and proliferation of mesothelial cells after injury by asbestos fibres.

[edit] Treatment

The prognosis for malignant mesothelioma remains disappointing, although there have been some modest improvements in prognosis from newer chemotherapies and multimodality treatments.[27] Treatment of malignant mesothelioma at earlier stages has a better prognosis, but cures are exceedingly rare. Clinical behavior of the malignancy is affected by several factors including the continuous mesothelial surface of the pleural cavity which favors local metastasis via exfoliated cells, invasion to underlying tissue and other organs within the pleural cavity, and the extremely long latency period between asbestos exposure and development of the disease. The histological subtype and the patient's age and health status also help predict prognosis.

[edit] Surgery

Surgery, by itself, has proved disappointing. In one large series, the median survival with surgery (including extrapleural pneumonectomy) was only 11.7 months.[27] However, research indicates varied success when used in combination with radiation and chemotherapy (Duke, 2008). (For more information on multimodality therapy with surgery, see below). A pleurectomy/decortication is the most common surgery, in which the lining of the chest is removed. Less common is an extrapleural pneumonectomy (EPP), in which the lung, lining of the inside of the chest, the hemi-diaphragm and the pericardium are removed.

Radiation


For patients with localized disease, and who can tolerate a radical surgery, radiation is often given post-operatively as a consolidative treatment. The entire hemi-thorax is treated with radiation therapy, often given simultaneously with chemotherapy. This approach of using surgery followed by radiation with chemotherapy has been pioneered by the thoracic oncology team at Brigham & Women's Hospital in Boston.[28] Delivering radiation and chemotherapy after a radical surgery has led to extended life expectancy in selected patient populations with some patients surviving more than 5 years. As part of a curative approach to mesothelioma, radiotherapy is also commonly applied to the sites of chest drain insertion, in order to prevent growth of the tumor along the track in the chest wall.

Although mesothelioma is generally resistant to curative treatment with radiotherapy alone, palliative treatment regimens are sometimes used to relieve symptoms arising from tumor growth, such as obstruction of a major blood vessel. Radiation therapy when given alone with curative intent has never been shown to improve survival from mesothelioma. The necessary radiation dose to treat mesothelioma that has not been surgically removed would be very toxic.


http://en.wikipedia.org/wiki/Mesothelioma

Mesothelioma Occupational

Occupational

Exposure to asbestos fibers has been recognized as an occupational health hazard since the early 1900s. Numerous epidemiological studies have associated occupational exposure to asbestos with the development of pleural plaques, diffuse pleural thickening, asbestosis, carcinoma of the lung and larynx, gastrointestinal tumors, and diffuse malignant mesothelioma of the pleura and peritoneum. Asbestos has been widely used in many industrial products, including cement, brake linings, gaskets, roof shingles, flooring products, textiles, and insulation.

Commercial asbestos mining at Wittenoom, Western Australia, occurred between 1945 and 1966. A cohort study of miners employed at the mine reported that while no deaths occurred within the first 10 years after crocidolite exposure, 85 deaths attributable to mesothelioma had occurred by 1985. By 1994, 539 reported deaths due to mesothelioma had been reported in Western Australia.
[edit] Paraoccupational secondary exposure

Family members and others living with asbestos workers have an increased risk of developing mesothelioma, and possibly other asbestos related diseases.[20] This risk may be the result of exposure to asbestos dust brought home on the clothing and hair of asbestos workers. To reduce the chance of exposing family members to asbestos fibres, asbestos workers are usually required to shower and change their clothing before leaving the workplace.
Asbestos in buildings

Many building materials used in both public and domestic premises prior to the banning of asbestos may contain asbestos. Those performing renovation works or DIY activities may expose themselves to asbestos dust. In the UK use of Chrysotile asbestos was banned at the end of 1999. Brown and blue asbestos was banned in the UK around 1985. Buildings built or renovated prior to these dates may contain asbestos materials.
[edit] Diagnosis
CT scan of a patient with mesothelioma, coronal section (the section follows the plane that divides the body in a front and a back half). The mesothelioma is indicated by yellow arrows, the central pleural effusion (fluid collection) is marked with a yellow star. Red numbers: (1) right lung, (2) spine, (3) left lung, (4) ribs, (5) descending part of the aorta, (6) spleen, (7) left kidney, (8) right kidney, (9) liver.
Micrograph of a pleural fluid cytopathology specimen showing mesothelioma.
Micrographs showing mesothelioma in a core biopsy.

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history. A history of exposure to asbestos may increase clinical suspicion for mesothelioma. A physical examination is performed, followed by chest X-ray and often lung function tests. The X-ray may reveal pleural thickening commonly seen after asbestos exposure and increases suspicion of mesothelioma. A CT (or CAT) scan or an MRI is usually performed. If a large amount of fluid is present, abnormal cells may be detected by cytopathology if this fluid is aspirated with a syringe. For pleural fluid, this is done by thoracentesis or tube thoracostomy (chest tube); for ascites, with paracentesis or ascitic drain; and for pericardial effusion with pericardiocentesis. While absence of malignant cells on cytology does not completely exclude mesothelioma, it makes it much more unlikely, especially if an alternative diagnosis can be made (e.g. tuberculosis, heart failure). Unfortunately, the diagnosis of malignant mesothelioma by cytology alone is difficult, even with expert pathologists.

Generally, a biopsy is needed to confirm a diagnosis of malignant mesothelioma. A doctor removes a sample of tissue for examination under a microscope by a pathologist. A biopsy may be done in different ways, depending on where the abnormal area is located. If the cancer is in the chest, the doctor may perform a thoracoscopy. In this procedure, the doctor makes a small cut through the chest wall and puts a thin, lighted tube called a thoracoscope into the chest between two ribs. Thoracoscopy allows the doctor to look inside the chest and obtain tissue samples. Alternatively, the chest surgeon might directly open the chest (thoracotomy). If the cancer is in the abdomen, the doctor may perform a laparoscopy. To obtain tissue for examination, the doctor makes a small incision in the abdomen and inserts a special instrument into the abdominal cavity. If these procedures do not yield enough tissue, more extensive diagnostic surgery may be necessary.

Immunohistochemical studies play an important role for the pathologist in differentiating malignant mesothelioma from neoplastic mimics. There are numerous tests and panels available. No single test is perfect for distinguishing mesothelioma from carcinoma or even benign versus malignant.
Typical immunohistochemistry results Positive Negative
EMA (epithelial membrane antigen) in a membranous distribution CEA (carcinoembryonic antigen)
WT1 (Wilms' tumour 1) B72.3
Calretinin MOC-3 1
Mesothelin-1 CD15
Cytokeratin 5/6 Ber-EP4
HBME-1 (human mesothelial cell 1) TTF-1 (thyroid transcription factor-1)

There are three histological types of malignant mesothelioma: (1) Epithelioid; (2) Sarcomatoid; and (3) Biphasic (Mixed). Epithelioid comprises about 50-60% of malignant mesothelioma cases and generally holds a better prognosis than the Sarcomatoid or Biphasic subtypes.[21]
[edit] Staging

Staging of mesothelioma is based on the recommendation by the International Mesothelioma Interest Group.[22] TNM classification of the primary tumor, lymph node involvement, and distant metastasis is performed. Mesothelioma is staged Ia–IV (one-A to four) based on the TNM status.[22][23]

Saturday, June 19, 2010

mesothelioma Cause

Working with asbestos is the major risk factor for mesothelioma.[5] In the United States, asbestos is the major cause of malignant mesothelioma and has been considered "indisputably"[6] associated with the development of mesothelioma. Indeed, the relationship between asbestos and mesothelioma is so strong that many consider mesothelioma a “signal” or “sentinel” tumor.[7][8][9][10] A history of asbestos exposure exists in most cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos. In rare cases, mesothelioma has also been associated with irradiation, intrapleural thorium dioxide (Thorotrast), and inhalation of other fibrous silicates, such as erionite. Some studies suggest that simian virus 40 (SV40) may act as a cofactor in the development of mesothelioma.[11]

Asbestos was known in antiquity, but it wasn't mined and widely used commercially until the late 1800s. Its use greatly increased during World War II. Since the early 1940s, millions of American workers have been exposed to asbestos dust. Initially, the risks associated with asbestos exposure were not publicly known. However, an increased risk of developing mesothelioma was later found among shipyard workers, people who work in asbestos mines and mills, producers of asbestos products, workers in the heating and construction industries, and other tradespeople. Today, the official position of the U.S. Occupational Safety and Health Administration (OSHA) and the U.S. EPA is that protections and "permissible exposure limits" required by U.S. regulations, while adequate to prevent most asbestos-related non-malignant disease, they are not adequate to prevent or protect against asbestos-related cancers such as mesothelioma.[12] Likewise, the British Government's Health and Safety Executive (HSE) states formally that any threshold for mesothelioma must be at a very low level and it is widely agreed that if any such threshold does exist at all, then it cannot currently be quantified. For practical purposes, therefore, HSE assumes that no such "safe" threshold exists. Others have noted as well that there is no evidence of a threshold level below which there is no risk of mesothelioma.[13] There appears to be a linear, dose-response relationship, with increasing dose producing increasing disease.[14] Nevertheless, mesothelioma may be related to brief, low level or indirect exposures to asbestos.[6] The dose necessary for effect appears to be lower for asbestos-induced mesothelioma than for pulmonary asbestosis or lung cancer.[6] Again, there is no known safe level of asbestos to asbestos as it relates to increased risk of mesothelioma.

The duration of exposure to asbestos causing mesothelioma can be short. For example, cases of mesothelioma have been documented with only 1–3 months of exposure[15][16]. People who work with asbestos wear personal protective equipment to lower their risk of exposure.

Latency, the time from first exposure to manifestation of disease, is prolonged in the case of mesothelioma. It is virtually never less than fifteen years and peaks at 30–40 years.[6] In a review of occupationally related mesothelioma cases, the median latency was 32 years.[17] Based upon the data from Peto et al, the risk of mesothelioma appears to increase to the third or fourth power from first exposure.[14]

Environmental exposures

Incidence of mesothelioma had been found to be higher in populations living near naturally occurring asbestos. For example, in central Cappadocia, Turkey, mesothelioma was causing 50% of all deaths in three small villages — Tuzköy, Karain and Sarıhıdır. Initially, this was attributed to erionite, a zeolite mineral with similar properties to asbestos, however, recently, detailed epidemiological investigation showed that erionite causes mesothelioma mostly in families with a genetic predisposition.[18][19] The documented presence of asbestos fibers in water supplies and food products has fostered concerns about the possible impact of long-term and, as yet, unknown exposure of the general population to these fibers.